Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Llovet, Josep M; De Baere, Thierry; Kulik, Laura; Haber, Philipp K; Greten, Tim F; Meyer, Tim; Lencioni, Riccardo

doi:10.1038/s41575-020-00395-0

Record: found
Abstract: found
Article: found

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Author(s): Josep M. Llovet , Thierry De Baere , Laura Kulik , Philipp K. Haber , Tim F. Greten , Tim Meyer , Riccardo Lencioni

Publication date (Electronic): January 28 2021

Journal: Nature Reviews Gastroenterology & Hepatology

Publisher: Springer Science and Business Media LLC

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Most cited references 192

Record: found
Abstract: not found
Article: not found

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Valérie Vilgrain, Peter Galle, Alejandro Forner … (2018)

0 comments Cited 2660 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S Finn, Shukui Qin, Masafumi Ikeda … (2020)

The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.